Methods, components and a set of elements in the management of erectile dysfunction

摘要

A Pharmaceutical composition for the treatment of male erectile dysfunction. Also, a method for providing such an Applicator and Pharmaceutical composition containing Said Pharmaceutical formulation. In addition, the use of the pharmaceutical Composition and the Applicator with the pharmaceutical composition for the treatment of male erectile dysfunction.Finally, a set of elements containing the Applicator comprising a Pharmaceutical composition for the treatment of male erectile dysfunction, a Refrigerant Container and instructions.Claim 1: a Pharmaceutical composition which comprises a vasoactive prostaglandin and pharmaceutically acceptable vehicle, where the vehicle iecitina comprises: (a), (b) and (c) isopropyl Palmitate, urea, where that vehicle further comprises either myristate is Opropilo or polaxu00e1mero, preferably polaxu00e1mero P 407And where the vehicle is formulated as a Cream with a viscosity at 25oC between 25000 and 200000 mPa.s.Claim 2: a Pharmaceutical composition according to claim 1, wherein the vasoactive prostaglandin prostaglandin E1 is selected from natural, Synthetic prostaglandin Synthetic prostaglandin E1, preferably, more preferably an alprostadil, deriv Ado function of any of these prostaglandins,Or any combination of these prostaglandins and / or a functional Derivative of the same. Claim 3: a Pharmaceutical composition according to claim 2, wherein the vasoactive prostaglandin is alprostadil.Claim 9: a method for preparing a Pharmaceutical Composition of any of claims 1 to 8, which comprises the steps of: a) providing a pharmaceutically acceptable vehicle, where the vehicle is formulated as a Cream with a viscosity of between 25oC 25 and 200 MPa. S, preferably between 40 and 150 MPa. S, most preferably between 50.000 and 100 MPa.S, where the vehicle iecitina comprises: (i), (ii) and (iii) isopropyl Palmitate, urea, and where the vehicle further comprises either a polaxu00e1mero Isopropyl Myristate or, preferably polaxu00e1mero P 407; b) providing a vasoactive prostaglandin, preferably alprostadilAnd a Solvent; c) The prostaglandin dissolve in the Solvent; and (d) MIX THE vasoactive prostaglandin dissolved with the vehicle, the vehicle where the PH is between 4.0 and 6.0, preferably between 4.5 and 5.5, and the pharmaceutical composition is cooled to approximately 35 And some do.